Evaxion Biotech (EVAX) has now completed the dosing of all 16 patients in its phase 2 trial with the company’s lead asset EVX-01. Designed with Evaxion’s AI-Immunology platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma. Dosing has been completed according to trial protocol and timelines, meaning the trial remains on track for completion and data readout in the second half of 2025. Coincidently, the first patient has now completed the trial and has had last visit according to the protocol. Patients will continue to be monitored and data collected.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech Announces ADS Ratio Change to Boost Liquidity
- Evaxion Biotech trading halted, news pending
- Upcoming Stock Splits This Week (January 13 to January 17) – Stay Invested
- Evaxion Biotech Amends ADS Ratio Change Effective Date
- Evaxion announces extension to January 14 of plan to implement ADS ratio change